ILLUMINA INC (ILMN)

Super Micro slides 7% after stock is dropped from Nasdaq 100

Super Micro is exiting the Nasdaq 100 after just five months in the index.

What's Going On With Illumina Stock On Monday?

On Friday, Nasdaq Inc’s (NASDAQ:NDAQ) annual reconstitution of the Nasdaq-100 Index will become effective before the market opens on December 23. Illumina, Inc. (NASDAQ:ILMN) was removed from the index. Year to date, the stock has increased around 8%, underperforming iShares Core S&P Mid-Cap ETF (NYSE:IJH). The provider of DNA sequencing and array-based technologies has been in the news due to its controversial multi-billion dollar deal to acquire cancer test maker Grail Inc (NASDAQ:GRAL). Also

Palantir Stock Is Joining the Nasdaq-100 Index, and Super Micro Computer Is Being Booted: What Investors Should Know

Palantir stock's huge rise this year has earned it a spot on another stock index.

MicroStrategy, Palantir Added to Nasdaq 100, Moderna Removed

MicroStrategy Inc., the dot-com-era software maker whose metamorphosis into a leveraged bet on Bitcoin has transfixed Wall Street, is joining the Nasdaq 100 Index, the benchmark’s overseer said Friday. Software company Palantir Technologies Inc. and Axon Enterprise Inc., a maker of Tasers and police body cameras, will also be added.

Palantir, MicroStrategy, and Axon Enterprise To Join Nasdaq 100

Palantir, MicroStrategy, and Axon Enterprise are set to join the Nasdaq 100 Index on Monday, Dec. 23, replacing Super Micro Computer, Moderna, and Illumina.

Illumina To Webcast Upcoming Investor Conference

/PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference: 43rd Annual J.P....

Illumina (ILMN) Down 9.3% Since Last Earnings Report: Can It Rebound?

Illumina (ILMN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Synaffix Licenses Metal-Free Click Chemistry Technology to Illumina for Next-Generation DNA Sequencing Applications

/PRNewswire/ -- Synaffix B.V., a Lonza company (SIX:LONN) focused on commercializing its clinical-stage bioconjugation platform technology for the development...

CD Genomics Enhances Whole Genome SNP Genotyping Services to Propel Genomic Discoveries

Myriad Genetics Announces Incorporation of its Proprietary HRD platform in Illumina’s Updated Comprehensive Gene Panel Assay, TruSight™ Oncology 500 v2

Agreement will expand worldwide access and better position Myriad’s GIS as a potential companion diagnostic across multiple potential tumor types

ILMN Stock Set to Gain From Expansion of TruSight Oncology Portfolio

Illumina's new TSO 500 v2 assay aims to enable CGP of tumors, bolstering its TruSight Oncology portfolio.

Illumina announces expansion of TruSight Oncology portfolio

/PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that it will release TruSight™...

Illumina To Webcast Upcoming Investor Conferences

/PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conferences: Wolfe Research 2024...

ILMN Q3 Earnings Top, '24 Sales View Down, Stock Dips in Aftermarket

Illumina's third- quarter revenues from the consumables business show robust growth, offset by the declining instruments business.

Illumina Reports Financial Results for Third Quarter of Fiscal Year 2024

Core Illumina revenue of $1.1 billion for Q3 2024, down 2% from Q3 2023 and on a constant currency basis Core Illumina GAAP operating margin of 68.6% and...